Kiniksa Pharmaceuticals/KNSA

$17.68

3.42%
-
1D1W1MYTD1YMAX

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).

Ticker

KNSA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sanjiv Patel

Employees

297

Headquarters

Hamilton, Bermuda

KNSA Metrics

BasicAdvanced
$1.21B
Market cap
106.88
P/E ratio
$0.16
EPS
0.35
Beta
-
Dividend rate
$1.21B
0.34687
$22.09
$10.65
362.51K
4.34
3.851
61.417
2.86%
3.37%
3.22%
106.884
4.467
2.745
2.863
91.653
22.74%
-93.82%

What the Analysts think about KNSA

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
62.61% upside
High $32.00
Low $25.00
$17.68
Current price
$28.75
Average price target

KNSA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
30.25% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$83.3M
24.33%
Net income
$25.2M
-282.61%
Profit margin
30.25%
-246.92%

KNSA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 350%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.18
$0.21
-$0.20
$0.35
-
Expected
-$0.21
-$0.17
-$0.17
-$0.14
-$0.16
Surprise
-13.25%
-225.37%
19.4%
-350%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Kiniksa Pharmaceuticals stock?

Kiniksa Pharmaceuticals (KNSA) has a market cap of $1.21B as of April 24, 2024.

What is the P/E ratio for Kiniksa Pharmaceuticals stock?

The price to earnings (P/E) ratio for Kiniksa Pharmaceuticals (KNSA) stock is 106.88 as of April 24, 2024.

Does Kiniksa Pharmaceuticals stock pay dividends?

No, Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next Kiniksa Pharmaceuticals dividend payment date?

Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders.

What is the beta indicator for Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals (KNSA) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Kiniksa Pharmaceuticals stock price target?

The target price for Kiniksa Pharmaceuticals (KNSA) stock is $28.75, which is 62.61% above the current price of $17.68. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Kiniksa Pharmaceuticals stock

Buy or sell Kiniksa Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing